An aggregon in conductin/axin2 regulates Wnt/β-catenin signaling and holds potential for cancer therapy
- PMID: 31534175
- PMCID: PMC6751202
- DOI: 10.1038/s41467-019-12203-8
An aggregon in conductin/axin2 regulates Wnt/β-catenin signaling and holds potential for cancer therapy
Abstract
The paralogous scaffold proteins axin and conductin/axin2 are key factors in the negative regulation of the Wnt pathway transcription factor β-catenin, thereby representing interesting targets for signaling regulation. Polymerization of axin proteins is essential for their activity in suppressing Wnt/β-catenin signaling. Notably, conductin shows less polymerization and lower activity than axin. By domain swapping between axin and conductin we here identify an aggregation site in the conductin RGS domain which prevents conductin polymerization. Induction of conductin polymerization by point mutations of this aggregon results in enhanced inhibition of Wnt/β-catenin signaling. Importantly, we identify a short peptide which induces conductin polymerization via masking the aggregon, thereby enhancing β-catenin degradation, inhibiting β-catenin-dependent transcription and repressing growth of colorectal cancer cells. Our study reveals a mechanism for regulating signaling pathways via the polymerization status of scaffold proteins and suggests a strategy for targeted colorectal cancer therapy.
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Gαi2-induced conductin/axin2 condensates inhibit Wnt/β-catenin signaling and suppress cancer growth.Nat Commun. 2022 Feb 3;13(1):674. doi: 10.1038/s41467-022-28286-9. Nat Commun. 2022. PMID: 35115535 Free PMC article.
-
Negative-feedback regulation of the Wnt pathway by conductin/axin2 involves insensitivity to upstream signalling.J Cell Sci. 2015 Jan 1;128(1):33-9. doi: 10.1242/jcs.159145. Epub 2014 Nov 6. J Cell Sci. 2015. PMID: 25380820
-
Cell cycle control of Wnt/β-catenin signalling by conductin/axin2 through CDC20.EMBO Rep. 2012 Apr;13(4):347-54. doi: 10.1038/embor.2012.12. EMBO Rep. 2012. PMID: 22322943 Free PMC article.
-
Toggling a conformational switch in Wnt/β-catenin signaling: regulation of Axin phosphorylation. The phosphorylation state of Axin controls its scaffold function in two Wnt pathway protein complexes.Bioessays. 2013 Dec;35(12):1063-70. doi: 10.1002/bies.201300101. Epub 2013 Sep 19. Bioessays. 2013. PMID: 24105937 Free PMC article. Review.
-
Control of beta-catenin signaling in tumor development.Ann N Y Acad Sci. 2000 Jun;910:21-33; discussion 33-5. doi: 10.1111/j.1749-6632.2000.tb06698.x. Ann N Y Acad Sci. 2000. PMID: 10911903 Review.
Cited by
-
Blocking the WNT/β-catenin pathway in cancer treatment:pharmacological targets and drug therapeutic potential.Heliyon. 2024 Aug 12;10(16):e35989. doi: 10.1016/j.heliyon.2024.e35989. eCollection 2024 Aug 30. Heliyon. 2024. PMID: 39253139 Free PMC article. Review.
-
Principles and functions of condensate modifying drugs.Front Mol Biosci. 2022 Nov 22;9:1007744. doi: 10.3389/fmolb.2022.1007744. eCollection 2022. Front Mol Biosci. 2022. PMID: 36483537 Free PMC article. Review.
-
Gαi2-induced conductin/axin2 condensates inhibit Wnt/β-catenin signaling and suppress cancer growth.Nat Commun. 2022 Feb 3;13(1):674. doi: 10.1038/s41467-022-28286-9. Nat Commun. 2022. PMID: 35115535 Free PMC article.
-
Upregulation of Parkin Accelerates Osteoblastic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells and Bone Regeneration by Enhancing Autophagy and β-Catenin Signaling.Front Cell Dev Biol. 2020 Sep 15;8:576104. doi: 10.3389/fcell.2020.576104. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33043010 Free PMC article.
-
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy.J Hematol Oncol. 2024 Jun 18;17(1):46. doi: 10.1186/s13045-024-01563-4. J Hematol Oncol. 2024. PMID: 38886806 Free PMC article. Review.
References
-
- Global Burden of Disease Cancer C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 4, 1553–1568 (2018). - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
